Trimetrexate.html |
| | | ca | | | de | | | en | | | es | | | fr | | | it | | | nl | | | no | | | pl | | | pt | | | ru | | | ro | | | fi | | | sv | | | tr | | | vo | | |
| |  |
 |
|
|
Trimetrexate
|
|
| Systematic (IUPAC) name | |
| 5-methyl-6-[(3,4,5-trimethoxyphenyl) aminomethyl] quinazoline-2,4-diamine | |
| Identifiers | |
| CAS number | |
| ATC code | P01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C19H23N5O3 |
| Mol. mass | 369.418 g/mol |
| Pharmacokinetic data | |
| Bioavailability | VD: 20-30 Liters |
| Metabolism | Oxidative O-demethylation, followed by conjugation with glucuronide or sulfate |
| Half life | 11 to 12 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Trimetrexate is a quinazoline derivative and dihydrofolate reductase inhibitor.
Uses
It has been used with leucovorin in treating pneumocystis pneumonia.1
It has been investigated for use in treating leiomyosarcoma.2
References
- ^ Sattler FR, Allegra CJ, Verdegem TD, et al (January 1990). "Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia". J. Infect. Dis. 161 (1): 91–6. PMID 2136905.
- ^ Smith HO, Blessing JA, Vaccarello L (January 2002). "Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group". Gynecol. Oncol. 84 (1): 140–4. doi:. PMID 11748990. http://linkinghub.elsevier.com/retrieve/pii/S0090825801964820.
External links
 |
This antimicrobial-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||